(19)
(11) EP 2 760 994 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
26.07.2017 Bulletin 2017/30

(45) Mention of the grant of the patent:
31.05.2017 Bulletin 2017/22

(21) Application number: 12836507.9

(22) Date of filing: 28.09.2012
(51) International Patent Classification (IPC): 
C12N 5/071(2010.01)
C12N 5/02(2006.01)
A61K 38/46(2006.01)
A61K 35/12(2015.01)
C12N 7/01(2006.01)
C12N 5/0789(2010.01)
C12N 15/86(2006.01)
(86) International application number:
PCT/US2012/057987
(87) International publication number:
WO 2013/049615 (04.04.2013 Gazette 2013/14)

(54)

COMPOUNDS FOR IMPROVED VIRAL TRANSDUCTION

VERBINDUNGEN FÜR VERBESSERTE VIRALE TRANSDUKTION

COMPOSÉS AMÉLIORANT LA TRANSDUCTION VIRALE


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 30.09.2011 US 201161541736 P

(43) Date of publication of application:
06.08.2014 Bulletin 2014/32

(60) Divisional application:
17173567.3

(73) Proprietor: Bluebird Bio, Inc.
Cambridge, MA 02142 (US)

(72) Inventors:
  • HEFFNER, Garrett Collins
    Boston Massachusetts 02215 (US)
  • BASSAN, Abraham Isaac
    Brookline Massachusetts 02446 (US)

(74) Representative: Goodfellow, Hugh Robin et al
Carpmaels & Ransford LLP One Southampton Row
London WC1B 5HA
London WC1B 5HA (GB)


(56) References cited: : 
WO-A1-2010/054271
US-A1- 2009 092 589
WO-A2-2004/098531
   
  • MOSTOSLAVSKY ET AL: "Efficiency of transduction of highly purified murine hematopoietic stem cells by lentiviral and oncoretroviral vectors under conditions of minimal in vitro manipulation", MOLECULAR THERAPY, NATURE PUBLISHING GROUP, GB, vol. 11, no. 6, 1 June 2005 (2005-06-01), pages 932-940, XP005002713, ISSN: 1525-0016, DOI: 10.1016/J.YMTHE.2005.01.005
  • GOESSLING W. ET AL.: 'Prostaglandin E2 enhances human cord blood stem cell xenotransplants and shows long-term safety in preclinical nonhuman primate transplant models' CELL STEM CELL vol. 8, 08 April 2011, pages 445 - 458, XP055002056
  • PELUS L.M. ET AL.: 'Pleiotropic effects of prostaglandin E2 in hematopoiesis; prostaglandin E2 and other eicosanoids regulate hematopoietic stem and progenitor cell function' PROSTAGLANDINS & OTHER LIPID MEDIATORS vol. 96, 2011, pages 3 - 9, XP028108764
  • N. Cartier ET AL: "Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy", Science, vol. 326, no. 5954, 6 November 2009 (2009-11-06), pages 818-823, XP055268270, US ISSN: 0036-8075, DOI: 10.1126/science.1171242
  • G. Puthenveetil ET AL: "Successful correction of the human -thalassemia major phenotype using a lentiviral vector", Blood, vol. 104, no. 12, 1 December 2004 (2004-12-01), pages 3445-3453, XP055216529, ISSN: 0006-4971, DOI: 10.1182/blood-2004-04-1427
  • PAWLIUK R ET AL: "Correction of sickle cell disease in transgenic mouse models of gene therapy", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 294, 14 December 2001 (2001-12-14), pages 2368-2371, XP002984304, ISSN: 0036-8075, DOI: 10.1126/SCIENCE.1065806
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).